Navigation Links
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
Date:2/19/2009

ny are forward-looking statements. Except as required by law, ISTA disclaims any intent or obligation to update any forward-looking statements. These forward-looking statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, among others: timely and successful implementation of ISTA's strategic initiatives; delays and uncertainties related to ISTA's research and development programs (including the difficulty of predicting the timing or outcome of product development efforts and the FDA or other regulatory agency approval or actions); uncertainties and risks regarding market acceptance of and demand for ISTA's approved products and the impact of competitive products and pricing; uncertainties and risks related to ISTA's ability to properly manage its growth; uncertainties and risks regarding the continued timely performance by ISTA's strategic partners of their respective obligations under existing collaborations and licensing arrangements; uncertainties and risks related to the continued availability of third party sourced products and raw materials on commercially reasonable terms, or at all; uncertainties and risks related to successful compliance with FDA and or other governmental regulations applicable to ISTA's facilities, products and/or business; uncertainties and risks related to the scope, validity, and enforceability of patents related to ISTA's products and technologies and the impact of patents and other intellectual property rights held by third parties; and such other risks and uncertainties as detailed from time to time in ISTA's public filings with the U.S. Securities and Exchange Commission, including but not limited to ISTA's Annual Report on Form 10-K for the year ended December 31, 2007, and its Forms 10-Q for the quarters ended Marc
'/>"/>
SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Victorian Hotel recently celebrated Valentine’s Day ... wanted to spend the auspicious day together. This Vancouver ... jump on Valentine’s Day with a sweet overnight package, ... their luxurious rooms. , The hotel started its ... a mouthwatering 3 course meal at Café 335. This ...
(Date:2/27/2015)... The UC Davis Huntington’s Disease Center, ... it a beacon of hope for people with Huntington’s ... by the national society committed to the values that ... of America — as a Level 1 Huntington’s Disease ... center’s service to over 300 families coping with Huntington's ...
(Date:2/27/2015)... “ Logical Operations ” was featured ... which takes a look at the latest and coolest ... a special reporter for NewsWatch and a technology expert, ... company helps companies avoid cyber security threats. , If ... see cyber security somewhere in the headlines. Well, cyber ...
(Date:2/27/2015)... Mirena IUD lawsuits ( http://www.mirenalawsuit2014.com/ ) ... perforations and other serious harm due to spontaneous migration ... in the multicounty litigation underway in New Jersey’s Bergen ... records indicate that the proceeding’s 34th Case Management Order ... that same day. (In Re: Mirena Litigation; Case No. ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Jupiter Medical ... pioneering partnership, Mount Sinai Heart New York at Jupiter ... research in South Florida. , “This innovative collaboration ... way we’re delivering unparalleled health care in our very ... Executive Officer of Jupiter Medical Center. “This kind of ...
Breaking Medicine News(10 mins):Health News:Victorian Hotel Celebrated Valentine’s Day in 2015 With Unique Overnight Deal 2Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 2Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 3Health News:A Way for Companies to Avoid Cyber Security Threats was Featured on NewsWatch Television on January 30, 2015 2Health News:Mirena Lawsuits Progress in New Jersey with Issuance of New Case Management Order, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Progress in New Jersey with Issuance of New Case Management Order, Bernstein Liebhard LLP Reports 3Health News:Jupiter Medical Center and Mount Sinai Heart New York Announce Landmark Partnership 2Health News:Jupiter Medical Center and Mount Sinai Heart New York Announce Landmark Partnership 3Health News:Jupiter Medical Center and Mount Sinai Heart New York Announce Landmark Partnership 4Health News:Jupiter Medical Center and Mount Sinai Heart New York Announce Landmark Partnership 5
... 8-year-old boy,living with epilepsy, and his mother Amy receive ... the exclusive sponsor of Canine,Assistants seizure response dogs. Through ... to play sports, take,music lessons, and learn Tae Kwon ... when his parents are not around is still a ...
... quick, non-invasive identification of the dangerous disease , , WEDNESDAY, ... be able to accurately, rapidly, and non-invasively diagnose lung ... the mouth, a new study suggests. , Oral cavity ... to be a highly accurate indicator of similar lung ...
... Mass., April 16 Xceed Molecular, a ... analysis,systems, announced that the University of Florida ... work with primary researchers,Charles Joel Rosser, MD ... of Surgery), to perform initial verification and ...
... Required to Provide Calorie Information, ALEXANDRIA, Va., ... today,s federal court ruling upholding,a New York City ... content of foods on their menus and menu ... to the regulation filed by the New York ...
... MONICA, Calif., April 16 Consumer,Watchdog today joined ... lawsuit alleging that health insurer Blue Cross engaged ... insurance of patients,after they got sick., The ... at least hundreds,of patients who have been left ...
... 16 MedCath Corporation,(Nasdaq: MDTH ) announced today ... of Directors., Mr. Grossman brings a wealth of ... Directors. He served as partner and health care,practice leader ... years with the firm. While with Pricewaterhouse Coopers, he ...
Cached Medicine News:Health News:Young Boy With Epilepsy to Gain Independence With New Seizure Response Dog From Canine Assistants 2Health News:Mouth Swab May One Day Diagnose Lung Cancer 2Health News:Mouth Swab May One Day Diagnose Lung Cancer 3Health News:Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer 2Health News:Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer 3Health News:Statement of the American Diabetes Association Supporting Federal Court's Ruling on New York City Proposal 2Health News:Consumer Watchdog Applauds L.A. City Attorney's Efforts to Reinstate Cancelled Blue Cross Patients; Urges State HMO Regulator to Do Same 2Health News:Woodrin 'Woody' Grossman Appointed to MedCath's Board of Directors 2
(Date:2/27/2015)... , Feb. 27, 2015  Two ... increasing in applications as their effectiveness is ... Kalorama Information.  Kalorama Information says that while ... the most powerful tool in proteomic biomarker ... MS) through its traditional techniques has struggled ...
(Date:2/26/2015)... Ill. , Feb. 26, 2015  AbbVie ... 15 abstracts of studies in its neuroscience and ... during the 67 th American Academy of ... , from April 18-25. The accepted abstracts ... DUOPA, in addition to investigational treatments in AbbVie,s ...
(Date:2/26/2015)... 26, 2015  Mail-service and specialty pharmacies will ... and government health plans $23.3 billion over the ... Pharmaceutical Care Management Association (PCMA). "Home ... of the easiest ways to reduce health costs," ... . "Policymakers should resist efforts to restrict these ...
Breaking Medicine Technology:Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... We offer a complete ... bringing laboratorians state-of-the-art monoclonal and ... the detection of enteric pathogens ... includes products for Clostridium difficile, ...
... The C. Difficile Tox A/B II ... Professional Diagnostics's exclusive Fecal-Quik-Prep device which greatly ... stool specimens for Tox A/B II testing. ... preparation/transfer device that greatly reduces the amount ...
... products for autoimmune testing feature single-well ANA ... as specific reflex tests including dsDNA, and ... (Ro), SS-B (La), Scl-70 and Jo-1. In ... full line of products for Cardiolipins (IgA, ...
Medicine Products: